Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA)

NCT06191848 · Recruiting

Last updated 2026-05-28

This clinical trial is testing whether a weekly injection of tirzepatide can reduce the need for knee replacement surgery in adults with both obesity and knee osteoarthritis.

Status Recruiting Currently enrolling participants.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 352 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2024-11 · est. completion 2037-05

Where 4 sites · Australia

What this study is testing ClinicalTrials.gov NCT06191848 ↗

Description as written by the study sponsor.

This is a trial of tirzepatide in people with obesity and knee osteoarthritis. The main purpose of this study is to see if tirzepatide can reduce number of these participants who require a knee replacement. Participants will be randomized to take a weekly injection of tirzepatide or a placebo for a total of 72 weeks.

Treatments tested

Tirzepatide Drug

Participants will receive tirzepatide subcutaneously
Placebo Drug

Participants will receive placebo subcutaneously

Main thing measured	Percentage of patients who undergo knee replacement in the target joint
Sponsor	University of Melbourne
Conditions studied	Obesity, Knee Osteoarthritis, Osteoarthritis, Knee
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06191848 ↗